Weekly Analysts’ Ratings Updates for Apogee Therapeutics (APGE)

Several analysts have recently updated their ratings and price targets for Apogee Therapeutics (NASDAQ: APGE):

• 6/24/2026 – Apogee Therapeutics had its “neutral” rating reaffirmed by Mizuho. They now have a $135.00 price target on the stock, up from $110.00.
• 6/24/2026 – Apogee Therapeutics was downgraded by Mizuho from “outperform” to “hold”. They now have a $135.00 price target on the stock, up from $110.00.
• 6/24/2026 – Apogee Therapeutics had its “hold” rating reaffirmed by Stifel Nicolaus. They now have a $135.00 price target on the stock, up from $133.00.
• 6/23/2026 – Apogee Therapeutics was downgraded by TD Cowen from “buy” to “hold”.
• 6/23/2026 – Apogee Therapeutics was downgraded by Guggenheim from “buy” to “neutral”.
• 6/23/2026 – Apogee Therapeutics was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $135.11 price target on the stock, up from $100.00.
• 6/23/2026 – Apogee Therapeutics was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $135.00 price target on the stock, up from $125.00.
• 6/22/2026 – Apogee Therapeutics was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”. They now have a $135.00 price target on the stock, up from $116.00.
• 6/22/2026 – Apogee Therapeutics was given a new $135.11 price target by Craig Hallum. They now have a “hold” rating on the stock.
• 6/22/2026 – Apogee Therapeutics was downgraded by Wedbush from “outperform” to “neutral”. They now have a $135.00 price target on the stock.
• 6/22/2026 – Apogee Therapeutics was downgraded by Citigroup Inc. from “strong-buy” to “hold”.
• 6/22/2026 – Apogee Therapeutics was downgraded by Canaccord Genuity Group Inc. from “buy” to “hold”. They now have a $135.11 price target on the stock, up from $130.00.
• 6/8/2026 – Apogee Therapeutics had its price target raised by Royal Bank Of Canada from $82.00 to $97.00. They now have a “sector perform” rating on the stock.
• 5/28/2026 – Apogee Therapeutics was given a new $89.00 price target by The Goldman Sachs Group, Inc..
• 5/28/2026 – Apogee Therapeutics was upgraded by The Goldman Sachs Group, Inc. to “hold”.
• 5/27/2026 – Apogee Therapeutics had its price target lowered by Truist Financial Corporation from $83.00 to $81.00. They now have a “hold” rating on the stock.
• 5/27/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $137.00 price target on the stock.
• 5/27/2026 – Apogee Therapeutics had its price target raised by Wedbush from $120.00 to $135.00. They now have an “outperform” rating on the stock.

Insider Activity

In other news, CEO Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $132.54, for a total value of $10,603,200.00. Following the completion of the transaction, the chief executive officer owned 1,015,987 shares of the company’s stock, valued at $134,658,916.98. This represents a 7.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the sale, the insider owned 179,248 shares of the company’s stock, valued at $23,768,284.80. This represents a 12.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 162,900 shares of company stock worth $19,038,985 over the last 90 days. Company insiders own 24.30% of the company’s stock.

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.